Is there a way to curb benzodiazepine addiction?

Swiss Medical Weekly

Volumn 141, Issue OCTOBER, 2011, Pages

  Lalive, Arnaud L ^a   Rudolph, Uwe ^b   Lus̈cher, Christian ^a,c   Tan, Kelly R ^a  

^a UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

^b HARVARD MEDICAL SCHOOL   (United States)

^c GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Addiction; Benzodiazepines; Ventral tegmental area

Indexed keywords

BENZODIAZEPINE DERIVATIVE;

AMNESIA; ANESTHESIA; ANXIETY DISORDER; CHRONIC DRUG ADMINISTRATION; DOPAMINERGIC NERVE CELL; DRUG ABUSE; DRUG DEPENDENCE; DRUG INDICATION; DRUG MECHANISM; DRUG SYNTHESIS; DRUG TOLERANCE; HISTORY OF MEDICINE; HUMAN; INSOMNIA; MUSCLE RELAXATION; NONHUMAN; REVIEW; REWARD; SEIZURE; ADDICTION; DRUG EFFECT; GENETICS; HISTORY; MESENCEPHALON;

BENZODIAZEPINES; DOPAMINERGIC NEURONS; HISTORY, 20TH CENTURY; HUMANS; MESENCEPHALON; SUBSTANCE-RELATED DISORDERS;

EID: 80655148788     PISSN: 14247860     EISSN: None     Source Type: Journal    
DOI: 10.4414/smw.2011.13277     Document Type: Review

References (61)

1. Sternbach LH. The benzodiazepine story. J Psychoactive Drugs. 1983;15:15-7. (Pubitemid 13035306)
2. Birdwood G, Craven M. Letter. Outmoded barbiturates. Br Med J. 1975;1:148.
3. Tan KR, Rudolph U, Lüscher C. Hooked on benzodiazepines: GABA(A) receptor subtypes and addiction. Trends in Neurosci. 2011;34:188-97.
4. Woods JH, Katz JL, Winger G. Benzodiazepines: use, abuse, and consequences. Pharmacol Rev. 1992;4:151-347.
5. Sigel E, Buhr A. The benzodiazepine binding site of GABAA receptors. Trends Pharmacol Sci. 1997;18:425-9. (Pubitemid 27521060)
6. Wieland HA, Lüddens H, Seeburg PH. A single histidine in GABAA receptors is essential for benzodiazepine agonist binding. J Biol Chem. 1992;267:1426-9.
7. Yang W, Drewe JA, Lan NC. Cloning and characterization of the human GABAA receptor alpha 4 subunit: identification of a unique diazepam-insensitive binding site. Eur J Pharmacol. 1995;291:319-25. (Pubitemid 3014599)
8. Korpi ER, Seeburg PH. Natural mutation of GABAA receptor alpha 6 subunit alters benzodiazepine affinity but not allosteric GABA effects. Eur J Pharmacol. 1993;247:23-7. (Pubitemid 23281229)
9. Rudolph U, Crestani F, Benke D, Brünig I, Benson JA, et al. Benzodiazepine actions mediated by specific gamma-aminobutyric acid(A) receptor subtypes. Nature. 1999;401:796-800.
10. McKernan RM, Rosahl TW, Reynolds DS, Sur C, Wafford KA, et al. Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABA(A) receptor alpha1 subtype. Nat Neurosci. 2000;3:587-92. (Pubitemid 30332078)
11. Löw K, Crestani F, Keist R, Benke D, Brünig I, et al. Molecular and neuronal substrate for the selective attenuation of anxiety. Science. 2000;290:131-4.
12. Crestani F, Löw K, Keist R, Mandelli M, Möhler H, et al. Molecular targets for the myorelaxant action of diazepam. Mol Pharmacol. 2001;59:442-5. (Pubitemid 32179921)
13. Crestani F, Keist R, Fritschy J-M, Benke D, Vogt K, et al. Trace fear conditioning involves hippocampal alpha5 GABA(A) receptors. Proc Nat Acad Sci. 2002;99:8980-5. (Pubitemid 34693669)
14. Collinson N, Kuenzi FM, Jarolimek W, Maubach KA, Cothliff R, et al. Enhanced learning and memory and altered GABAergic synaptic transmission in mice lacking the alpha 5 subunit of the GABAA receptor. J Neurosci. 2002;22:5572-80. (Pubitemid 35386478)
15. Cheng VY, Martin LJ, Elliott EM, Kim JH, Mount HTJ, et al. Alpha5GABAA receptors mediate the amnestic but not sedative-hypnotic effects of the general anesthetic etomidate. J Neurosci. 2006;26:3713-20.
16. Tan KR, Brown M, Labouèbe G, Yvon C, Creton C, et al. Neural bases for addictive properties of benzodiazepines. Nature. 2010;463:769-74.
17. Salzman C. Addiction to benzodiazepines. The Psychiatric quarterly. 1998;69:251-61. (Pubitemid 28460420)
18. Pétursson H. The benzodiazepine withdrawal syndrome. Addiction. 1994;89:1455-9. (Pubitemid 24343905)
19. Gabbard GO. (2007) American Psychiatric Publishing 209-211.
20. http://en.wikipedia.org/wiki/Benzodiazepines - cite-note-isbn0-19-856667- 0-85.
21. Colvin R. United States of America: Addicus Books (2008)74-76.
22. Wagner FA, Anthony JC. From first drug use to drug dependence; developmental periods of risk for dependence upon marijuana, cocaine, and alcohol. Neuropsychopharmacology. 2002;26:479-88. (Pubitemid 34260997)
23. Rooney S, Kelly G, Bamford L, Sloan D, O'Connor JJ. Co-abuse of opiates and benzodiazepines. Ir J Med Sc. 1999;168:1,36-41. (Pubitemid 29094953)
24. Prescott CA, Kendler KS. Genetic and environmental contributions to alcohol abuse and dependence in a population-based sample of male twins. Am J Psy. 1999;156:34-40. (Pubitemid 29034877)
25. Enoch MA. Goldman D. The genetics of alcoholism and alcohol abuse. Cur Psy Rep. 2001;3:144-51.
26. Goldman D, Oroszi G, Ducci F. The genetics of addictions: uncovering the genes. Nat Rev Gen. 2005;6:521-32. (Pubitemid 40910429)
27. Merikangas KR, Mehta RL, Molnar BE, Walters EE, Swendsen JD, et al. Comorbidity of substance use disorders with mood and anxiety disorders: results of the International Consortium in Psychiatric Epidemiology. Add Behav. 1998;23:893-907. (Pubitemid 28443200)
28. Hu X, Oroszi G, Chun J, Smith TL, Goldman D, et al. An expanded evaluation of the relationship of four alleles to the level of response to alcohol and the alcoholism risk. Alc Clin Exp Res. 2005;29:8-16. (Pubitemid 40129206)
29. Schuckit MA, Mazzanti C, Smith TL, Ahmed U, Radel M, et al. Selective genotyping for the role of 5-HT2A, 5-HT2C, and GABA alpha 6 receptors and the serotonin transporter in the level of response to alcohol: a pilot study. Biol Psy. 1999;45:647-51. (Pubitemid 29147375)
30. Iwata N, Cowley DS, Radel M, Roy-Byrne PP, Goldman D. Relationship between a GABAA alpha 6 Pro385Ser substitution and benzodiazepine sensitivity. Am J Psy. 1999;156:1447-9. (Pubitemid 29416547)
31. White FJ, Kalivas PW. Neuroadaptations involved in amphetamine and cocaine addiction. Drug Alc Dep. 1998;51:141-53. (Pubitemid 28353762)
32. Nestler EJ. Molecular neurobiology of addiction. Am J Psy. 2001;10:201-17. (Pubitemid 32879087)
33. McClung CA, Nestler EJ. Regulation of gene expression and cocaine reward by CREB and DeltaFosB. Nat Neurosci. 2003;6:1208-15. (Pubitemid 37346042)
34. McClung CA, Ulery PG, Perrotti LI, Zachariou V, Berton O, et al. DeltaFosB: a molecular switch for long-term adaptation in the brain. Brain Res Mol Brain Res. 2004;132:146-54. (Pubitemid 39586757)
35. Nestler EJ. Review. Transcriptional mechanisms of addiction: role of DeltaFosB. Biol Sci. 2008;363:3245-55.
36. Maze I, Nestler EJ. The epigenetic landscape of addiction. Annals New York Acad Sci. 2011;1216:99-113.
37. Ungless MA, Whistler JL, Malenka RC, Bonci A. Single cocaine exposure in vivo induces long-term potentiation in dopamine neurons. Nature. 2001;411:583-7. (Pubitemid 32531404)
38. Lüscher C, Malenka RC. Drug-evoked synaptic plasticity in addiction: from molecular changes to circuit remodeling. Neuron. 2011;69:650-63.
39. Yamaguchi T, Sheen W, Morales M. Glutamatergic neurons are present in the rat ventral tegmental area. Eur J Neurosci. 2007;25:106-18. (Pubitemid 46096227)
40. Schultz W, Dayan P, Montague PR. A neural substrate of prediction and reward. Science. 1997;275:1593-9. (Pubitemid 27120526)
41. Ungless MA, Magill PJ, Bolam JP. Uniform inhibition of dopamine neurons in the ventral tegmental area by aversive stimuli. Science. 2004;303:2040-2. (Pubitemid 38393283)
42. Xia Y, Driscoll JR, Wilbrecht L, Margolis EB, Fields HL, Hjelmstad GO. Nucleus accumbens medium spiny neurons target non-dopaminergic neurons in the ventral tegmental area. J Neurosci. 2011;31 (21):7811-6.
43. Di Chiara G, Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Nat Acad Sci. 1988;85:5274-8.
44. Nestler EJ. Is there a common molecular pathway for addiction? Nat. Neurosci. 2005;8:1445-9. (Pubitemid 41573654)
45. Di Chiara G, Bassareo V, Fenu S, De Luca MA, Spina L, et al. Dopamine and drug addiction: the nucleus accumbens shell connection. Neuropharmacol. 2004;47(Suppl 1):227-41. (Pubitemid 39298267)
46. Argilli E, Sibley DR, Malenka RC, England PM, Bonci A. Mechanism and time course of cocaine-induced long-term potentiation in the ventral tegmental area. J Neurosci. 2008;28:9092-100.
47. Brown MTC, Bellone C, Mameli M, Labouèbe G, Bocklisch C, et al. Drug-Driven AMPA Receptor Redistribution Mimicked by Selective Dopamine Neuron Stimulation. PLoS ONE 2010;5: e15870.
48. Lüscher C, Ungless MA. The mechanistic classification of addictive drugs. PLoS Med. 2006;3:e437.
49. Johnson SW, North RA. Opioids excite dopamine neurons by hyperpolarization of local interneurons. J Neurosci. 1992;12:483-8.
50. Szabo B, Siemes S, Wallmichrath I. Inhibition of GABAergic neurotransmission in the ventral tegmental area by cannabinoids. Euro J Neurosci. 2002;15:2057-61. (Pubitemid 35471896)
51. Cruz HG, Ivanova T, Lunn M-L, Stoffel M, Slesinger PA, et al. Bi-directional effects of GABA(B) receptor agonists on the mesolimbic dopamine system. Nat Neurosci. 2004;7:153-9. (Pubitemid 38129791)
52. Maskos U, Molles BE, Pons S, Besson M, Guiard BP, et al. Nicotine reinforcement and cognition restored by targeted expression of nicotinic receptors. Nature. 2005;436:103-7. (Pubitemid 40966193)
53. Sulzer D, Sonders MS, Poulsen NW, Galli A. Mechanisms of neurotransmitter release by amphetamines: a review. Prog Neurobiol. 2005;75:406-33. (Pubitemid 40834286)
54. Saal D, Dong Y, Bonci A, Malenka RC. Drugs of abuse and stress trigger a common synaptic adaptation in dopamine neurons. Neuron. 2003;37:577-82. (Pubitemid 36262980)
55. Mameli M, Halbout B, Creton C, Engblom D, Parkitna JR, et al. Cocaine-evoked synaptic plasticity: persistence in the VTA triggers adaptations in the NAc. Nat Neurosci. 2009;12:1036-41.
56. Liu Q-, Pu L, Poo M. Repeated cocaine exposure in vivo facilitates LTP induction in midbrain dopamine neurons. Nature. 2005;437:1027-31. (Pubitemid 41486984)
57. Wolf ME. The Bermuda Triangle of cocaine-induced neuroadaptations. Trends Neurosci. 2010;33:391-8.
58. Heikkinen AE, Möykkynen TP, Korpi ER. Long-lasting modulation of glutamatergic transmission in VTA dopamine neurons after a single dose of benzodiazepine agonists. Neuropsychopharmacology. 2009;34:290-8.
59. Anderson KN, Shneerson JM. Drug treatment of REM sleep behavior disorder: the use of drug therapies other than clonazepam. J Clinic Sleep Med. 2009;5:235-9.
60. Hollister LE, Müller-Oerlinghausen B, Rickels K, Shader RI. Clinical uses of benzodiazepines. J Clinic Psychopharmacol. 1993;13:1S-169S.
61. Scott-Stevens P, Atack JR, Sohal B, Worboys P. Rodent pharmacokinetics and receptor occupancy of the GABAA receptor subtype selective benzodiazepine site ligand L-838417. Biopharma Drug Disp. 2005;26:13-20. (Pubitemid 40201967)